These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14743892)

  • 21. [The treatment of hepatitis C].
    Orlent H; Vrolijk JM; de Man RA; Schalm SW
    Ned Tijdschr Geneeskd; 2003 Jun; 147(25):1208-13. PubMed ID: 12848055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
    Dollarhide AW; Loh C; Leckband SG; Endow-Eyer R; Robinson S; Meyer JM
    J Clin Gastroenterol; 2007 Mar; 41(3):322-8. PubMed ID: 17426475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute hepatitis C: current status and remaining challenges.
    Santantonio T; Wiegand J; Gerlach JT
    J Hepatol; 2008 Oct; 49(4):625-33. PubMed ID: 18706735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of hepatitis C: history, presence and future.
    Vrolijk JM; de Knegt RJ; Veldt BJ; Orlent H; Schalm SW
    Neth J Med; 2004 Mar; 62(3):76-82. PubMed ID: 15209471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.
    Farrell GC
    J Gastroenterol Hepatol; 2007 May; 22(5):607-10. PubMed ID: 17444844
    [No Abstract]   [Full Text] [Related]  

  • 29. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C: natural history, diagnosis, and management.
    Lam NP
    Am J Health Syst Pharm; 1999 May; 56(10):961-73; quiz 974-5. PubMed ID: 10365720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of hepatitis C.
    Smith C
    Minn Med; 2003 Jun; 86(6):53-6. PubMed ID: 12834215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016].
    Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
    Orv Hetil; 2017 Feb; 158(Suppl 1):3-22. PubMed ID: 28218867
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.
    Xirouchakis E; Triantos C; Manousou P; Sigalas A; Calvaruso V; Corbani A; Leandro G; Patch D; Burroughs A
    J Viral Hepat; 2008 Oct; 15(10):699-709. PubMed ID: 18673428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office.
    ; Yee HS; Currie SL; Darling JM; Wright TL
    Am J Gastroenterol; 2006 Oct; 101(10):2360-78. PubMed ID: 17032203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Benefits of a preventive psychiatric accompaniment in patients Hepatitis C Virus seropositive (HCV): prospective study concerning 39 patients].
    Lang JP; Meyer N; Doffoel M
    Encephale; 2003; 29(4 Pt 1):362-5. PubMed ID: 14615706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral therapy for patients with chronic hepatitis C.
    Heathcote J
    Semin Liver Dis; 2000; 20(2):185-99. PubMed ID: 10946423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antiviral therapy of hepatitis C].
    Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
    Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.